RT Journal Article
T1 Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study.
A1 Alcaraz, Antonio
A1 Rodríguez-Antolín, Alfredo
A1 Carballido-Rodríguez, Joaquín
A1 Castro-Díaz, David
A1 Esteban-Fuertes, Manuel
A1 Cózar-Olmo, José M
A1 Ficarra, Vincenzo
A1 Medina-López, Rafael
A1 Fernández-Gómez, Jesús M
A1 Angulo, Javier C
A1 Medina-Polo, José
A1 Brenes-Bermúdez, Francisco J
A1 Molero-García, José M
A1 Fernández-Pro-Ledesma, Antonio
A1 Manasanch, José
A1 The Qualiprost Study Group, On Behalf Of
K1 BII
K1 BPH
K1 combination treatment
K1 hexanic extract of Serenoa repens
K1 moderate-severe LUTS
K1 quality of life
K1 storage symptoms
K1 tamsulosin
K1 tolerability
AB To investigate whether tamsulosin (TAM) and the hexanic extract of Serenoa repens (HESr) are more effective in combination than as monotherapy in men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). Subset analysis of data from a 6-month, multicenter observational study. Patients received either tamsulosin (0.4 mg/day) or HESr (320 mg/day) alone or in combination. Primary endpoints were change in symptoms and quality of life. Tolerability was also assessed. Seven hundred and nine patients were available for intention to treat (ITT) analysis, 263 treated with tamsulosin, 262 with HESr, and 184 with TAM + HESr. After 6 months, International Prostate Symptom Score (IPSS) scores improved by a mean (standard deviation) of 7.2 (5.0) points in the TAM + HESr group compared to 5.7 (4.3) points with TAM alone and 5.4 (4.6) points with HESr (p
SN 2077-0383
YR 2020
FD 2020-09-09
LK https://hdl.handle.net/10668/26501
UL https://hdl.handle.net/10668/26501
LA en
DS RISalud
RD Apr 17, 2025